EP2591340B1 - Ensemble optique et procédé pour déterminer une concentration d'analyte - Google Patents
Ensemble optique et procédé pour déterminer une concentration d'analyte Download PDFInfo
- Publication number
- EP2591340B1 EP2591340B1 EP11730057.4A EP11730057A EP2591340B1 EP 2591340 B1 EP2591340 B1 EP 2591340B1 EP 11730057 A EP11730057 A EP 11730057A EP 2591340 B1 EP2591340 B1 EP 2591340B1
- Authority
- EP
- European Patent Office
- Prior art keywords
- light
- interface
- optical
- assembly according
- tissue sample
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Not-in-force
Links
- 230000003287 optical effect Effects 0.000 title claims description 66
- 239000012491 analyte Substances 0.000 title claims description 22
- 238000000034 method Methods 0.000 title claims description 20
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 68
- 239000008103 glucose Substances 0.000 claims description 68
- 238000012544 monitoring process Methods 0.000 claims description 18
- 238000005102 attenuated total reflection Methods 0.000 claims description 15
- 238000001228 spectrum Methods 0.000 claims description 11
- 210000001124 body fluid Anatomy 0.000 claims description 9
- 239000010839 body fluid Substances 0.000 claims description 9
- 238000012545 processing Methods 0.000 claims description 6
- 230000001419 dependent effect Effects 0.000 claims description 5
- WUKWITHWXAAZEY-UHFFFAOYSA-L calcium difluoride Chemical compound [F-].[F-].[Ca+2] WUKWITHWXAAZEY-UHFFFAOYSA-L 0.000 claims description 3
- 229910001634 calcium fluoride Inorganic materials 0.000 claims description 3
- 239000011248 coating agent Substances 0.000 claims description 3
- 238000000576 coating method Methods 0.000 claims description 3
- 229920000052 poly(p-xylylene) Polymers 0.000 claims description 3
- 210000001519 tissue Anatomy 0.000 description 35
- 239000000523 sample Substances 0.000 description 34
- 239000008280 blood Substances 0.000 description 27
- 210000004369 blood Anatomy 0.000 description 27
- 238000002835 absorbance Methods 0.000 description 23
- 206010012601 diabetes mellitus Diseases 0.000 description 15
- 230000008033 biological extinction Effects 0.000 description 12
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 12
- 230000008859 change Effects 0.000 description 11
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 10
- 210000003722 extracellular fluid Anatomy 0.000 description 7
- 238000005259 measurement Methods 0.000 description 7
- 230000010363 phase shift Effects 0.000 description 7
- 210000000434 stratum corneum Anatomy 0.000 description 7
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 6
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 6
- 239000004202 carbamide Substances 0.000 description 6
- 102000004877 Insulin Human genes 0.000 description 5
- 108090001061 Insulin Proteins 0.000 description 5
- 238000010521 absorption reaction Methods 0.000 description 5
- 238000000862 absorption spectrum Methods 0.000 description 5
- 230000005684 electric field Effects 0.000 description 5
- 229940125396 insulin Drugs 0.000 description 5
- 230000035945 sensitivity Effects 0.000 description 5
- 239000011358 absorbing material Substances 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 210000000245 forearm Anatomy 0.000 description 4
- 230000036571 hydration Effects 0.000 description 4
- 238000006703 hydration reaction Methods 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 230000035515 penetration Effects 0.000 description 4
- 238000004458 analytical method Methods 0.000 description 3
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 3
- 210000003491 skin Anatomy 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 150000003626 triacylglycerols Chemical class 0.000 description 3
- 210000003462 vein Anatomy 0.000 description 3
- 238000004497 NIR spectroscopy Methods 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 210000002615 epidermis Anatomy 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 239000007943 implant Substances 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 238000007920 subcutaneous administration Methods 0.000 description 2
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 2
- PFNQVRZLDWYSCW-UHFFFAOYSA-N (fluoren-9-ylideneamino) n-naphthalen-1-ylcarbamate Chemical compound C12=CC=CC=C2C2=CC=CC=C2C1=NOC(=O)NC1=CC=CC2=CC=CC=C12 PFNQVRZLDWYSCW-UHFFFAOYSA-N 0.000 description 1
- NCGICGYLBXGBGN-UHFFFAOYSA-N 3-morpholin-4-yl-1-oxa-3-azonia-2-azanidacyclopent-3-en-5-imine;hydrochloride Chemical compound Cl.[N-]1OC(=N)C=[N+]1N1CCOCC1 NCGICGYLBXGBGN-UHFFFAOYSA-N 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- 208000013016 Hypoglycemia Diseases 0.000 description 1
- 206010033372 Pain and discomfort Diseases 0.000 description 1
- 208000017442 Retinal disease Diseases 0.000 description 1
- 206010038923 Retinopathy Diseases 0.000 description 1
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 description 1
- 230000002745 absorbent Effects 0.000 description 1
- 239000002250 absorbent Substances 0.000 description 1
- 239000006096 absorbing agent Substances 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 235000013405 beer Nutrition 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 238000009534 blood test Methods 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 230000023852 carbohydrate metabolic process Effects 0.000 description 1
- 235000021256 carbohydrate metabolism Nutrition 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 229910003460 diamond Inorganic materials 0.000 description 1
- 239000010432 diamond Substances 0.000 description 1
- 210000000624 ear auricle Anatomy 0.000 description 1
- 238000002848 electrochemical method Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 150000002303 glucose derivatives Chemical class 0.000 description 1
- 125000002791 glucosyl group Chemical group C1([C@H](O)[C@@H](O)[C@H](O)[C@H](O1)CO)* 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 201000001421 hyperglycemia Diseases 0.000 description 1
- 230000002218 hypoglycaemic effect Effects 0.000 description 1
- 238000002329 infrared spectrum Methods 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 230000001678 irradiating effect Effects 0.000 description 1
- 238000000691 measurement method Methods 0.000 description 1
- 238000004476 mid-IR spectroscopy Methods 0.000 description 1
- 208000015122 neurodegenerative disease Diseases 0.000 description 1
- 239000013307 optical fiber Substances 0.000 description 1
- 238000005375 photometry Methods 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000000159 protein binding assay Methods 0.000 description 1
- 239000013074 reference sample Substances 0.000 description 1
- SBIBMFFZSBJNJF-UHFFFAOYSA-N selenium;zinc Chemical compound [Se]=[Zn] SBIBMFFZSBJNJF-UHFFFAOYSA-N 0.000 description 1
- 238000004611 spectroscopical analysis Methods 0.000 description 1
- 239000012086 standard solution Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
- 210000000707 wrist Anatomy 0.000 description 1
Images
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N21/00—Investigating or analysing materials by the use of optical means, i.e. using sub-millimetre waves, infrared, visible or ultraviolet light
- G01N21/17—Systems in which incident light is modified in accordance with the properties of the material investigated
- G01N21/55—Specular reflectivity
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/145—Measuring characteristics of blood in vivo, e.g. gas concentration, pH value; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid, cerebral tissue
- A61B5/14532—Measuring characteristics of blood in vivo, e.g. gas concentration, pH value; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid, cerebral tissue for measuring glucose, e.g. by tissue impedance measurement
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/145—Measuring characteristics of blood in vivo, e.g. gas concentration, pH value; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid, cerebral tissue
- A61B5/1455—Measuring characteristics of blood in vivo, e.g. gas concentration, pH value; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid, cerebral tissue using optical sensors, e.g. spectral photometrical oximeters
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N21/00—Investigating or analysing materials by the use of optical means, i.e. using sub-millimetre waves, infrared, visible or ultraviolet light
- G01N21/17—Systems in which incident light is modified in accordance with the properties of the material investigated
- G01N21/55—Specular reflectivity
- G01N21/552—Attenuated total reflection
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N21/00—Investigating or analysing materials by the use of optical means, i.e. using sub-millimetre waves, infrared, visible or ultraviolet light
- G01N21/17—Systems in which incident light is modified in accordance with the properties of the material investigated
- G01N21/25—Colour; Spectral properties, i.e. comparison of effect of material on the light at two or more different wavelengths or wavelength bands
- G01N21/31—Investigating relative effect of material at wavelengths characteristic of specific elements or molecules, e.g. atomic absorption spectrometry
- G01N21/35—Investigating relative effect of material at wavelengths characteristic of specific elements or molecules, e.g. atomic absorption spectrometry using infrared light
Definitions
- the present invention relates to an optical assembly and method for determining the concentration of an analyte in body fluid and particularly, but not exclusively, to an optical assembly and method for determining the concentration of glucose in body fluid.
- Diabetes mellitus which is commonly known as diabetes, is the name for a group of chronic diseases that affect the way the body uses food to make the energy necessary for life. Diabetes is primarily a disruption of carbohydrate metabolism with the result that the blood glucose level of a person may vary considerably, from 40mM (720mg/dl) to as low as 1mM (18mg/dl). In comparison, the blood glucose level of a person without diabetes varies very little, remaining between 4mM and 8mM.
- Self blood glucose monitoring is used by Type I diabetics in the home to detect hypoglycemia and hyperglycemia, and therefore to determine the corrective action required, such as taking extra food to raise the blood glucose concentration or extra insulin to lower the blood glucose concentration. These measurements, which are made using low-cost, hand-held blood glucose monitors, also allow the physician to adjust the insulin dosage at appropriate times so as to maintain near normoglycemia.
- self blood glucose monitoring is used to inform newly diagnosed non-insulin dependent patients about their condition, how to manage it and to monitor themselves with daily or weekly readings as necessary.
- These blood glucose monitors use either reflective photometry or an electrochemical method to measure blood glucose concentration.
- the finger or earlobe of the patient is typically pricked with a sterile lancet and a small sample of blood is placed on the test strip. After analysis, the monitor displays the blood glucose concentration.
- the main disadvantages of self blood glucose monitoring systems are poor patient acceptance because the technique is painful, only intermittent assessment of diabetic control is possible and readings during the night or when the patient is otherwise occupied are not possible.
- NIR near infrared
- NIR spectroscopy suffers from interference by other optical absorbers in the tissue and is also dependent on blood flow in the skin.
- the absorbance peaks of water at these wavelengths are variable in position with temperature such that shifts in water absorbance induced by temperature changes of less than a degree are greater than those induced by a 20mg/dl variation in glucose concentration.
- an optical waveguide such as a plate, a prism, or optical fibre may pass light along its length by the process of total internal reflection.
- n 2 is the refractive index of the region outside the prism
- n 1 is the refractive index of the prism.
- an evanescent wave penetrates a small distance into the surrounding medium. It is therefore possible to obtain an absorption spectrum for the regions of the surrounding medium in contact with the outer surface of the prism, by comparing the light incident upon the prism with that emerging therefrom.
- ATR attenuated total reflectance
- a conventional ATR arrangement is illustrated in Figure 1 of the drawings.
- the substance to be investigated e.g. tissue
- an absorbing material 12 is placed on the surface of the prism 10, an evanescent wave (not shown) is found to penetrate into the material and this evanescent wave is found to attenuate the total internal reflection.
- n ⁇ n + ik
- i the ⁇ (-1)
- Interstitial fluid namely the fluid disposed between cells within a tissue sample is known to have a glucose concentration that correlates with the blood glucose concentration.
- the maximum sensitivity to analyte absorbance within a tissue sample occurs at or just greater than the critical angle. If the angle is reduced, ATR becomes insensitive to the analyte, i.e. no measurement of analyte concentration is possible.
- the penetration depth ⁇ of the wave into the absorbing material namely the depth to which an electric field associated with the evanescent wave decays to 1/ e (approx 37%) of the value at the surface of the material, reduces significantly as the incident angle increases to the critical angle and beyond.
- Fingertips typically have stratum corneum thickness of up to 400 ⁇ m.
- the value of ⁇ is typically only 3 ⁇ m so that the effective penetration depth for most subjects is insufficient for making a measurement of analyte concentration.
- a measuring apparatus which comprises a light source, an ATR element for irradiating a sample with a light from the light source, receiving the light returning from the sample and emitting the received light, an incident angle controlling section installed between the light source and the ATR element and adjusting an incident angle of the light entering from the light source to the ATR element, a light detecting section for detecting the light emitted from the ATR element, a refraction index calculating section for calculating a complex refraction index of the sample from the light detected by the light detecting section, an electric field calculating section for calculating an electric field distribution indicating a relationship between a depth and an electric field strength within the sample from the calculated complex refraction index, and a storage section for storing an electric field distribution of a reference sample.
- an optical assembly for the non-invasive determination of a concentration of an analyte in a tissue sample, the assembly comprising an optical arrangement comprising a first optical interface for reflecting light incident thereon and a second optical interface for reflecting light incident thereon, the light reflected from the first and second interfaces being arranged to combine to generate an interference pattern characteristic of a difference in phase between light reflected from the first interface with the light reflected from the second interface, wherein the second interface comprises an interface between an optical element of the arrangement and the tissue sample.
- the light reflected from the second interface will comprise a phase shift with respect to the light reflected from the first interface and this phase shift is dependent on the extinction coefficient k of the tissue sample which relates to the glucose concentration in the interstitial fluid of the tissue, for example.
- the optical assembly further comprises a light source, such as a broadband laser source, for launching light upon the first and second interface.
- the light source may comprise a quantum cascade laser and is arranged to generate light having a wavelength range in the infra-red region of the electromagnetic spectrum.
- the assembly preferably further comprises monitoring means for monitoring the interference between the light from the first and second interface.
- the monitoring means which may include an IR detector or spectrum analyser is arranged to analyse the interference pattern created by the light reflected from the first and second interfaces.
- the assembly further comprises processing means for processing the interference to determine the concentration of the analyte in the tissue sample.
- the optical arrangement comprises a first optical element and a second optical element, the first and second elements being coupled together to form the first interface therebetween, the second element being arranged to contact a surface portion of the tissue to form a second interface, wherein, the second element comprises a refractive index which is greater than a refractive index of the first element and the surface portion of the tissue.
- a second element having a larger refractive index than the first element and the tissue sample ensures that light which is incident upon the second interface is incident at an angle less than the critical angle for total internal reflection in the second element, and therefore penetrates beyond the stratum corneum to the required depth for absorption by the analyte in the tissue sample.
- the light is preferably launched upon the first interface at an angle such that the light refracted into the second element becomes incident upon the second interface at an angle less than the critical angle for total internal reflection of the light within the second element.
- the second element is thin compared with the first element, and preferably comprises a film disposed upon the first element.
- the thickness of the second element is preferably dependent on the wavelength of the incident light.
- the first element preferably comprises calcium fluoride and second element preferably comprises parylene.
- the optical arrangement preferably comprises an interferometer comprising a first and second element for reflecting light incident thereon, and a routing device which is arranged to route a first component of the light incident thereon toward the first element and a second component of the light incident thereon toward the second element, the first and second elements comprising a front and rear reflecting surface, wherein the front surface of each element comprises an anti-reflection coating for minimising any reflection of light off the front surface of the respective element and the rear surface of the second element is arranged to contact the tissue sample.
- the first interface of the second embodiment preferably comprises an interface of the rear surface of the first element with air, and the second interface comprises an interface between the rear surface of the second element with the tissue sample.
- the interference pattern is characteristic of a difference in phase of the light incident on the second element with the light reflected off the second element.
- the first and second elements of the first and second embodiments are preferably substantially transmissive for wavelengths in the infr-red region of the electromagnetic spectrum.
- the analyte comprises glucose
- a method for the non-invasive determination of the concentration of an analyte in a tissue sample comprising the steps of:
- the method comprises the use of attenuated total reflectance.
- a glucose monitor for the non-invasive determination of the concentration of glucose in a tissue sample, the monitor comprising an optical assembly according to the first aspect, a light source for launching light upon the first and second interfaces and monitoring means for monitoring the light which becomes reflected off the first and second interfaces.
- an optical assembly 100a according to a first embodiment of the present invention comprising an optical arrangement 110a, for the non-invasive determination of the concentration of an analyte, such as glucose, in a tissue sample, such as body fluid.
- an analyte such as glucose
- the optical arrangement 110a illustrated comprises a substantially rectangular cuboid shape however, it is to be appreciated that other shapes may also be used.
- the arrangement comprises a first, relatively thick layer 120 of calcium fluoride, for example and a second, relatively thin layer 130 of parylene for example, disposed upon the first layer 120 and coupled thereto to form an interface 140 between the first and second layers 120, 130.
- the first and second layers 120, 130 are substantially transmissive to light in the infra-red region of the spectrum, namely in the wavelength range 1-10 ⁇ m, such that light in this wavelength range can pass through the first and second layers 120, 130.
- the assembly 100a further comprises a collimated light source 150, such as an incandescent light source or quantum cascade laser for producing a broad range of wavelengths over the infra-red region of the spectrum, and monitoring means 160 such as an infra-red detector and/or spectrum analyzer for monitoring the light which becomes reflected out from the arrangement 110a.
- a collimated light source 150 such as an incandescent light source or quantum cascade laser for producing a broad range of wavelengths over the infra-red region of the spectrum
- monitoring means 160 such as an infra-red detector and/or spectrum analyzer for monitoring the light which becomes reflected out from the arrangement 110a.
- the stratum corneum (not shown) comprises a thickness of approximately 400 ⁇ m on the finger tips (not shown), however a recent study has found that the stratum corneum (not shown) on the volar forearm (not shown) rarely exceeds 18 ⁇ m. Accordingly, during use the optical arrangement 110a is placed upon the volar forearm (not shown) with the second layer 130 in contact therewith and infra-red light is directed upon the interface 140 between the first and second layer 120, 130, from the first layer 120.
- the refractive index of the second layer 130 is chosen to be greater than that of the first layer 120 and the portion of the forearm (not shown) in contact with the second layer 130, and the light is incident upon the interface 140 at an angle which ensures that the light becomes refracted into the second layer 130 at an angle less than the critical angle for total internal reflection within the second layer 130.
- the light which passes into the second layer 130 is arranged to subsequently strike the interface 170 between the second layer 130 and the tissue 180 and partially penetrate into the tissue 180.
- the light will decay as it propagates into the forearm (not shown).
- the light will also partially reflect from the interface 170 between the second layer 130 and the tissue 180 and pass back toward the interface 140 between the first and second layers 120, 130, whereupon a similar partial reflection and transmission will occur.
- the light which reflects from the optical arrangement 110a will therefore comprise a component reflected from the interface 140 between the first and second layers 120, 130 and a component from the interface 170 between the second layer 130 and the tissue 180.
- the light reflected from the interface 140 between the layers 120, 130 will have constant amplitude and phase whereas the light reflected from the interface 170 with the tissue 180 will comprise a phase shift characteristic of the extinction coefficient k of the tissue sample 180.
- This relative phase shift between the reflected components will manifest as an interference pattern which is monitored using the detector and/or spectrum analyser 160 and subsequently processed using a processor 190 to determine glucose concentration in the interstitial fluid.
- Interstitial fluid typically consists of water, salts, glucose, lactate, urea and triglycerides, and water has been shown to comprise a substantially uniform absorption in the mid-IR range (6-10 ⁇ m, wave number 1600-1000cm-1).
- the method according to an embodiment of the present invention compensates for the effects of the hydration levels of the skin, both directly in terms of the water absorbance and indirectly in terms of the effect of hydration on the absorbance of the stratum corneum (not shown) and other analytes present in the interstitial fluid (not shown).
- Salts do not absorb in this wavelength range whereas glucose, lactate, urea and triglycerides all have strong absorbance.
- Each of these analytes has characteristic IR spectra, one example of which is the absorption spectrum for glucose, as illustrated in Figure 5 of the drawings.
- water is first placed on the second layer 130 of the arrangement 110a and the absorbance measured and recorded at 3 ⁇ m and in the range 5-10 ⁇ m.
- Standard solutions of glucose, lactate and urea are subsequently and separately placed on the second layer 130 of the arrangement 110a and the absorbance measured and recorded in the range 5-10 ⁇ m.
- This calibration data is then stored for subsequent retrieval during use. If necessary, the calibration data for water and glucose can be repeated by the end user.
- a tissue A total - A water - A glucose - A lactate - A urea
- the total absorbance measured during the subsequent non-invasive determination of blood glucose levels can then be recorded and a least squares analysis software program is used to extract the glucose concentration, since all other sources of absorbance will have been accounted for.
- an optical assembly 200 for the non-invasive determination of the concentration of an analyte, such as glucose, in a tissue sample.
- the assembly 200 comprises an optical arrangement 210 and a broadband light source 150, such as a broadband laser which is arranged to launch laser light having a wavelength characteristic of infra-red wavelengths.
- the optical arrangement 210 comprises an interferometer comprising a beam splitter 220 which is arranged to partially reflect and partially transmit incident laser light toward a first and second reflector element 230, 240, respectively.
- the reflector elements 230, 240 may be formed of zinc selenide and comprise substantially planar element.
- the elements 230, 240 are orientated to reflect the light incident thereon back toward the beam splitter 220, substantially along the same path as the incident light. In this respect, the elements 230, 240 are orientated substantially perpendicular to the direction of the light incident thereon.
- the light returned to the beam splitter 220 from the elements 230, 240 is then recombined and directed toward a detector 250, such as a spectrum analyzer.
- the light reflected from the elements 230, 240 will comprise a component reflected from the front 230a, 240a and rear surfaces 230b, 240b thereof, which due to the optical path length associated with the thickness of the respective element 230, 240, will give rise to a phase shift between the component reflected off the front surface 230a, 240a and the component reflected off the rear surface 230b, 240b, and thus interference from each reflector 230, 240.
- the front surface 230a, 240a of each reflector is coated with an anti-reflection coating 260 to minimise the reflection of the light from the front surfaces 230a, 240a.
- the resulting interference from the combination of the light from each reflector 230, 240 will therefore be due to the difference in optical path length arising from the separation of the rear surface 230b, 240b of the elements 230, 240 from the beam splitter 220.
- One of the elements 230, 240 of the interferometer is arranged to move with respect to the beam splitter 220 along the direction indicated by arrow A-A, to adjust the separation therebetween to tune the optical path length difference to correspond with an integral number of wavelengths, and thus to ensure that the light re-combines at the beam splitter 220 in phase to create a strong optical signal.
- a sample 270 is then placed in contact with the rear surface 240b of the fixed element such that the light which is incident on the rear surface 240b illuminates the sample 270.
- the light which is incident on the sample 270 will partially transmit into the sample 270 and become absorbed therein due to the extinction coefficient.
- this will ensure maximum penetration into the sample 270, so that the light becomes absorbed by the analytes within the sample 270.
- the light will also partially reflect at the sample/element interface 280 and will undergo a phase shift characteristic of the absorbance of the light in the sample 270.
- the light which is incident upon the rear surface 230b of the first element 230, will encounter an interface 290 with air and will therefor undergo no phase change.
- the absorbance has been shown above to be proportional to the extinction coefficient of the light in the sample 270. Accordingly, the resulting interference of the light from the first and second reflectors 230, 240 will be characteristic of the phase shift of the light at the sample/element interface 280 and thus the extinction coefficient, which has been shown above to be related to the glucose concentration in body fluid, for example.
- optical element, assembly and method according to the above described embodiments of the present invention provides for a simple yet effective means of determining glucose concentration in body fluid non-invasively.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Physics & Mathematics (AREA)
- General Health & Medical Sciences (AREA)
- Pathology (AREA)
- Biophysics (AREA)
- Surgery (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Molecular Biology (AREA)
- Optics & Photonics (AREA)
- Medical Informatics (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Heart & Thoracic Surgery (AREA)
- Chemical & Material Sciences (AREA)
- Biochemistry (AREA)
- Analytical Chemistry (AREA)
- Immunology (AREA)
- General Physics & Mathematics (AREA)
- Emergency Medicine (AREA)
- Spectroscopy & Molecular Physics (AREA)
- Measurement Of The Respiration, Hearing Ability, Form, And Blood Characteristics Of Living Organisms (AREA)
Claims (15)
- Un ensemble optique (100) pour la détermination non invasive d'une concentration d'un analyte tel que glucose dans un échantillon de tissu (180), l'ensemble comprenant un agencement optique (110) comprenant une première interface optique (140) destinée à réfléchir une lumière incidente sur celle-ci et une deuxième interface optique (170) destinée à réfléchir une lumière incidente sur celle-ci, la lumière réfléchie à partir des première et deuxième interfaces étant agencée de façon à se combiner pour générer un diagramme d'interférence caractéristique d'une différence en phase entre une lumière réfléchie à partir de la première interface avec la lumière réfléchie à partir de la deuxième interface, où la deuxième interface comprend une interface entre un élément optique de l'agencement et l'échantillon de tissu,
où l'agencement optique comprend un premier élément optique (120) et un deuxième élément optique (130), les premier et deuxième éléments étant couplés ensemble de façon à former la première interface entre eux, le deuxième élément étant agencé de façon à entrer en contact avec une partie de surface du tissu de façon à former la deuxième interface, où le deuxième élément comprend un indice de réfraction qui est supérieur à un indice de réfraction du premier élément et de la partie de surface du tissu. - Un ensemble optique selon la Revendication 1, comprenant en outre un moyen de surveillance (160) pour la surveillance de l'interférence entre la lumière provenant de la première interface et de la deuxième interface.
- Un ensemble selon la Revendication 1 ou 2, comprenant en outre un moyen de traitement (190) pour le traitement de l'interférence de façon à déterminer la concentration de l'analyte dans l'échantillon de tissu.
- Un ensemble selon la Revendication 1, agencé de sorte qu'une lumière soit envoyée sur la première interface à un angle de sorte que la lumière réfractée dans le deuxième élément devienne incidente sur la deuxième interface à un angle inférieur à l'angle critique pour une réflexion interne totale de la lumière à l'intérieur du deuxième élément.
- Un ensemble optique selon la Revendication 1 ou 4, où le deuxième élément est mince comparé au premier élément.
- Un ensemble optique selon l'une quelconque des Revendications précédentes, où l'épaisseur du deuxième élément dépend de la longueur d'onde de la lumière incidente.
- Un ensemble optique selon l'une quelconque des Revendications précédentes, où le premier élément contient du fluorure de calcium et le deuxième élément contient du parylène.
- Un ensemble optique (100) pour la détermination non invasive d'une concentration d'un analyte tel que glucose dans un échantillon de tissu (180), l'ensemble comprenant un agencement optique (110) comprenant une première interface optique (140) destinée à réfléchir une lumière incidente sur celle-ci et une deuxième interface optique (170) destinée à réfléchir une lumière incidente sur celle-ci, la lumière réfléchie à partir des première et deuxième interfaces étant agencée de façon à se combiner pour générer un diagramme d'interférence caractéristique d'une différence en phase entre une lumière réfléchie à partir de la première interface avec la lumière réfléchie à partir de la deuxième interface, où la deuxième interface comprend une interface entre un élément optique de l'agencement et l'échantillon de tissu, où
l'agencement optique comprend un premier élément optique (120) et un deuxième élément optique (130),
l'agencement optique comprend un interféromètre possédant un premier et un deuxième éléments destinés à réfléchir une lumière incidente sur ceux-ci, et un dispositif d'acheminement qui est agencé de façon à acheminer un premier composant de la lumière incidente sur celui-ci vers le premier élément et un deuxième composant de la lumière incidente sur celui-ci vers le deuxième élément,
le deuxième élément étant agencé de façon à entrer en contact avec une partie de surface du tissu de façon à former la deuxième interface, où le deuxième élément comprend un indice de réfraction qui est supérieur à un indice de réfraction du premier élément et de la partie de surface du tissu. - Un ensemble optique selon la Revendication 8, les premier et deuxième éléments comprenant une surface réfléchissante avant et arrière, où la surface avant de chaque élément comprend un revêtement antireflet destiné à minimiser toute réflexion de lumière provenant de la surface avant de l'élément respectif, et la surface arrière du deuxième élément est agencée de façon à entrer en contact avec l'échantillon de tissu.
- Un ensemble optique selon la Revendication 8 ou 9, où la première interface comprend une interface de la surface arrière du premier élément avec l'air, et la deuxième interface comprend une interface entre la surface arrière du deuxième élément avec l'échantillon de tissu.
- Un ensemble optique selon la Revendication 8, 9 ou 10, où le diagramme d'interférence est caractéristique d'une différence en phase de la lumière incidente sur le deuxième élément avec la lumière réfléchie à partir du deuxième élément.
- Un ensemble optique selon l'une quelconque des Revendications précédentes, où les premier et deuxième éléments sont sensiblement transmissifs pour des longueurs d'onde dans la zone infrarouge du spectre électromagnétique.
- Un procédé de détermination non invasive de la concentration d'un analyte dans un échantillon de tissu au moyen d'un agencement optique selon l'une quelconque des Revendications précédentes, le procédé comprenant les opérations suivantes :a) l'agencement du deuxième élément de l'agencement optique en contact avec l'échantillon de tissu,b) l'envoi d'une lumière sur les première et deuxième interfaces optiques,c) la surveillance de l'interférence entre la lumière qui devient réfléchie à partir des première et deuxième interfaces optiques, etd) le traitement de la lumière surveillée de façon à déterminer la concentration d'un analyte dans le liquide corporel.
- Un procédé selon la Revendication 13, où le procédé comprend l'utilisation d'une réflectance totale atténuée.
- Un glucomètre destiné à la détermination non invasive de la concentration de glucose dans un liquide corporel, le glucomètre comprenant un ensemble optique selon l'une quelconque des Revendications 1 à 12, une source lumineuse destinée à envoyer de la lumière vers les première et deuxième interfaces et un moyen de surveillance destiné à la surveillance de la lumière qui devient réfléchie à partir des première et deuxième interfaces.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB1011459.3A GB201011459D0 (en) | 2010-07-07 | 2010-07-07 | Optical element, assembly and method for determining analyte concentration |
GBGB1105045.7A GB201105045D0 (en) | 2010-07-07 | 2011-03-25 | Optical assembly and method for determining analyte concentration |
PCT/GB2011/051246 WO2012004586A1 (fr) | 2010-07-07 | 2011-07-01 | Ensemble optique et procédé pour déterminer une concentration d'analyte |
Publications (2)
Publication Number | Publication Date |
---|---|
EP2591340A1 EP2591340A1 (fr) | 2013-05-15 |
EP2591340B1 true EP2591340B1 (fr) | 2014-12-31 |
Family
ID=42712060
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP11730057.4A Not-in-force EP2591340B1 (fr) | 2010-07-07 | 2011-07-01 | Ensemble optique et procédé pour déterminer une concentration d'analyte |
Country Status (4)
Country | Link |
---|---|
US (1) | US8970843B2 (fr) |
EP (1) | EP2591340B1 (fr) |
GB (3) | GB201011459D0 (fr) |
WO (1) | WO2012004586A1 (fr) |
Families Citing this family (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR101627444B1 (ko) * | 2012-02-29 | 2016-06-03 | 고쿠리츠다이가쿠호우징 카가와다이가쿠 | 분광 특성 측정 장치 및 분광 특성 측정 방법 |
JP6117506B2 (ja) * | 2012-10-09 | 2017-04-19 | 国立大学法人 東京大学 | テラヘルツ波測定装置及び方法 |
DE102013008400B4 (de) * | 2013-05-04 | 2015-03-05 | SAMTD GmbH & Co. KG | Verfahren und Vorrichtung zur nicht-invasiven Bestimmung einer Messgröße eines Analyten in einem biologischen Körper |
KR101584128B1 (ko) * | 2014-03-03 | 2016-01-11 | 광주과학기술원 | 시료 집합체 및 이를 이용한 광학 상수 측정 장치 |
KR102247499B1 (ko) | 2015-01-14 | 2021-05-03 | 삼성전자주식회사 | 시료 접촉면적 측정장치를 구비한 감쇠 전반사 분광분석 장치 및 방법 |
US10413182B2 (en) | 2015-07-24 | 2019-09-17 | Johnson & Johnson Vision Care, Inc. | Biomedical devices for biometric based information communication |
US20170119287A1 (en) * | 2015-07-24 | 2017-05-04 | Johnson & Johnson Vision Care, Inc. | Quantum-dot spectrometers for use in biomedical devices and methods of use |
KR102444674B1 (ko) * | 2015-11-20 | 2022-09-16 | 삼성전자주식회사 | 광학 측정 장치 및 이를 구비하는 전자 기기 |
JP7080480B2 (ja) * | 2018-07-19 | 2022-06-06 | 有限会社ティ・エス・イー | 非侵襲血中糖計測計 |
ES2774983B2 (es) | 2019-01-22 | 2021-06-10 | Univ Sevilla | Dispositivo portable y metodo para la estimacion no invasiva del nivel de glucosa en sangre |
Family Cites Families (25)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3436159A (en) * | 1966-02-04 | 1969-04-01 | Bausch & Lomb | Internal reflection element for spectroscopy with film optical cavity to enhance absorption |
US5028787A (en) | 1989-01-19 | 1991-07-02 | Futrex, Inc. | Non-invasive measurement of blood glucose |
US5342789A (en) | 1989-12-14 | 1994-08-30 | Sensor Technologies, Inc. | Method and device for detecting and quantifying glucose in body fluids |
US5362966A (en) | 1990-06-27 | 1994-11-08 | Rosenthal Robert D | Measurement of finger temperature in near-infrared quantitative measurement instrument |
DE4227813A1 (de) * | 1992-08-21 | 1994-02-24 | Kim Yoon Ok | Vorrichtung zur qualitativen und/oder quantitativen Bestimmung einer zu analysierenden Probe |
US5736410A (en) * | 1992-09-14 | 1998-04-07 | Sri International | Up-converting reporters for biological and other assays using laser excitation techniques |
US5604581A (en) * | 1994-10-07 | 1997-02-18 | On-Line Technologies, Inc. | Film thickness and free carrier concentration analysis method and apparatus |
WO1998014771A1 (fr) * | 1996-09-30 | 1998-04-09 | Aventis Research & Technologies | Capteur optique pour detecter des substances chimiques dissoutes ou dispersees dans l'eau |
IL131903A0 (en) * | 1999-09-15 | 2001-03-19 | Technion Res & Dev Foundation | Plasmon resonance phase imaging |
US6567768B1 (en) * | 2000-06-30 | 2003-05-20 | Intel Corporation | Determining an extent to which an electronic device has been operated |
GB0119062D0 (en) * | 2001-08-06 | 2001-09-26 | Cambridge Consultants | Interferometer |
EP1464273B1 (fr) | 2003-04-03 | 2006-11-29 | Matsushita Electric Industrial Co., Ltd. | Méthode et appareil pour mesurer la concentration d'un composant spécifique |
US7751594B2 (en) * | 2003-04-04 | 2010-07-06 | Lumidigm, Inc. | White-light spectral biometric sensors |
US20040225206A1 (en) * | 2003-05-09 | 2004-11-11 | Kouchnir Mikhail A. | Non-invasive analyte measurement device having increased signal to noise ratios |
FI20031143A0 (fi) * | 2003-08-08 | 2003-08-08 | Wallac Oy | Optinen fokusointimenetelmä ja -järjestely |
US20050137469A1 (en) * | 2003-12-17 | 2005-06-23 | Berman Herbert L. | Single detector infrared ATR glucose measurement system |
JP2005188999A (ja) | 2003-12-24 | 2005-07-14 | Matsushita Electric Ind Co Ltd | 特定成分の濃度測定装置、特定成分の濃度測定方法 |
JP3980608B2 (ja) * | 2004-10-29 | 2007-09-26 | シャープ株式会社 | 鏡面光沢予測装置、鏡面光沢予測方法、鏡面光沢予測装置の制御プログラム、および、記録媒体 |
JP2006275994A (ja) | 2005-03-04 | 2006-10-12 | Toshiba Corp | 光学式グルコースセンサチップ |
US8673650B2 (en) * | 2005-12-09 | 2014-03-18 | Ridge Diagnostics, Inc. | Optical molecular detection |
KR101359169B1 (ko) * | 2006-03-16 | 2014-02-05 | 구라시키 보세키 가부시키가이샤 | 전반사 감쇠형 광학 프로브 및 그것을 이용한 수용액 분광 측정 장치 |
US8004676B1 (en) * | 2007-02-09 | 2011-08-23 | The Research Foundation Of State University Of New York | Method for detecting analytes using surface plasmon resonance |
US8730468B2 (en) | 2008-02-01 | 2014-05-20 | Rare Light, Inc. | Methods, devices and kits for peri-critical reflectance spectroscopy |
US8096647B2 (en) * | 2008-09-22 | 2012-01-17 | Xerox Corporation | Solid ink sticks having a verification interlock for verifying position of a solid ink stick before identifying the ink stick |
JP5028529B2 (ja) * | 2008-10-14 | 2012-09-19 | 国立大学法人東北大学 | 試料分析方法 |
-
2010
- 2010-07-07 GB GBGB1011459.3A patent/GB201011459D0/en not_active Ceased
-
2011
- 2011-03-25 GB GBGB1105045.7A patent/GB201105045D0/en not_active Ceased
- 2011-07-01 US US13/808,635 patent/US8970843B2/en not_active Expired - Fee Related
- 2011-07-01 EP EP11730057.4A patent/EP2591340B1/fr not_active Not-in-force
- 2011-07-01 WO PCT/GB2011/051246 patent/WO2012004586A1/fr active Application Filing
- 2011-07-01 GB GB1111212.5A patent/GB2482378A/en not_active Withdrawn
Also Published As
Publication number | Publication date |
---|---|
US8970843B2 (en) | 2015-03-03 |
WO2012004586A1 (fr) | 2012-01-12 |
GB201011459D0 (en) | 2010-08-25 |
GB2482378A (en) | 2012-02-01 |
GB201105045D0 (en) | 2011-05-11 |
EP2591340A1 (fr) | 2013-05-15 |
GB201111212D0 (en) | 2011-08-17 |
US20130155410A1 (en) | 2013-06-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP2591340B1 (fr) | Ensemble optique et procédé pour déterminer une concentration d'analyte | |
US6424851B1 (en) | Infrared ATR glucose measurement system (II) | |
US7016713B2 (en) | Non-invasive determination of direction and rate of change of an analyte | |
US6662030B2 (en) | Non-invasive sensor having controllable temperature feature | |
EP0548418B1 (fr) | Détermination non-invasive de la concentration de glucose dans le corps d'un patient | |
US6353226B1 (en) | Non-invasive sensor capable of determining optical parameters in a sample having multiple layers | |
US6718189B2 (en) | Method and apparatus for non-invasive blood analyte measurement with fluid compartment equilibration | |
JP2021037321A (ja) | 血中物質濃度測定装置及び導光部 | |
EP0160768A1 (fr) | Dispositif spectrophotométrique pour la détermination, par voie non-invasive, de glucose dans les tissus vivants | |
US20080269575A1 (en) | Method and Apparatus for Monitoring Bodily Analytes | |
JP2005095317A (ja) | 光学測定装置及びそれを用いた血糖値測定装置 | |
JP2011519635A (ja) | 光学マイクロニードル系分光計 | |
WO2006079797A2 (fr) | Dispositif permettant de mesurer la concentration d'un melange a analyser | |
WO1997043947A1 (fr) | Controle d'analysats de tissus par rayonnement infrarouge | |
EP1094745A1 (fr) | Mesure non invasive d'analytes sanguins | |
US20040225206A1 (en) | Non-invasive analyte measurement device having increased signal to noise ratios | |
US20050137469A1 (en) | Single detector infrared ATR glucose measurement system | |
JP2011220993A (ja) | 近赤外分光分析装置 | |
Janik et al. | Photonic blood glucose measurement with infrared quantum cascade lasers: A novel non‐invasive and pain‐free glucometer for diabetes patients | |
Shih et al. | Introduction to spectroscopy for noninvasive glucose sensing | |
Ali | FEASIBILITY STUDY ON DEVELOPING AN OPTICAL FIBRE-BASED, NON-INVASIVE, ELECTRO-TEXTILE SENSOR FOR DETECTING BLOOD GLUCOSE |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
17P | Request for examination filed |
Effective date: 20130108 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR |
|
DAX | Request for extension of the european patent (deleted) | ||
17Q | First examination report despatched |
Effective date: 20131025 |
|
GRAP | Despatch of communication of intention to grant a patent |
Free format text: ORIGINAL CODE: EPIDOSNIGR1 |
|
INTG | Intention to grant announced |
Effective date: 20140717 |
|
GRAS | Grant fee paid |
Free format text: ORIGINAL CODE: EPIDOSNIGR3 |
|
GRAA | (expected) grant |
Free format text: ORIGINAL CODE: 0009210 |
|
AK | Designated contracting states |
Kind code of ref document: B1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR |
|
REG | Reference to a national code |
Ref country code: CH Ref legal event code: EP Ref country code: GB Ref legal event code: FG4D |
|
REG | Reference to a national code |
Ref country code: IE Ref legal event code: FG4D |
|
REG | Reference to a national code |
Ref country code: AT Ref legal event code: REF Ref document number: 704689 Country of ref document: AT Kind code of ref document: T Effective date: 20150215 |
|
REG | Reference to a national code |
Ref country code: DE Ref legal event code: R096 Ref document number: 602011012720 Country of ref document: DE Effective date: 20150219 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: NO Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20150331 Ref country code: LT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20141231 Ref country code: FI Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20141231 |
|
REG | Reference to a national code |
Ref country code: NL Ref legal event code: VDEP Effective date: 20141231 |
|
REG | Reference to a national code |
Ref country code: LT Ref legal event code: MG4D |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: SE Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20141231 Ref country code: HR Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20141231 Ref country code: LV Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20141231 Ref country code: RS Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20141231 Ref country code: GR Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20150401 |
|
REG | Reference to a national code |
Ref country code: AT Ref legal event code: MK05 Ref document number: 704689 Country of ref document: AT Kind code of ref document: T Effective date: 20141231 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: NL Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20141231 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: CZ Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20141231 Ref country code: RO Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20141231 Ref country code: ES Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20141231 Ref country code: SK Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20141231 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: IS Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20150430 Ref country code: PL Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20141231 Ref country code: AT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20141231 |
|
REG | Reference to a national code |
Ref country code: DE Ref legal event code: R097 Ref document number: 602011012720 Country of ref document: DE |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: DK Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20141231 Ref country code: EE Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20141231 |
|
PLBE | No opposition filed within time limit |
Free format text: ORIGINAL CODE: 0009261 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT |
|
26N | No opposition filed |
Effective date: 20151001 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: IT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20141231 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: MC Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20141231 Ref country code: SI Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20141231 |
|
REG | Reference to a national code |
Ref country code: CH Ref legal event code: PL |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: LU Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20150701 |
|
REG | Reference to a national code |
Ref country code: IE Ref legal event code: MM4A |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: CH Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20150731 Ref country code: LI Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20150731 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: BE Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20141231 |
|
REG | Reference to a national code |
Ref country code: FR Ref legal event code: PLFP Year of fee payment: 6 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: IE Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20150701 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: MT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20141231 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: SM Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20141231 Ref country code: HU Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT; INVALID AB INITIO Effective date: 20110701 Ref country code: BG Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20141231 |
|
REG | Reference to a national code |
Ref country code: FR Ref legal event code: PLFP Year of fee payment: 7 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: CY Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20141231 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: TR Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20141231 |
|
REG | Reference to a national code |
Ref country code: FR Ref legal event code: PLFP Year of fee payment: 8 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: MK Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20141231 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: PT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20141231 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: FR Payment date: 20180612 Year of fee payment: 8 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: AL Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20141231 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: DE Payment date: 20180619 Year of fee payment: 8 Ref country code: GB Payment date: 20180531 Year of fee payment: 8 |
|
REG | Reference to a national code |
Ref country code: DE Ref legal event code: R119 Ref document number: 602011012720 Country of ref document: DE |
|
GBPC | Gb: european patent ceased through non-payment of renewal fee |
Effective date: 20190701 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: DE Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20200201 Ref country code: GB Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20190701 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: FR Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20190731 |